1. Introduction {#section0005}
===============

Community-acquired pneumonia (CAP) still remains one of the most important causes of death, especially in older adults and those with co-morbid diseases, despite advances in modern medicine [@bib1], [@bib2]. Since CAP is a condition with significant mortality and morbidity, early and effective antimicrobial treatment has been a major focus in clinical practice [@bib1]. Pathogen distribution and antimicrobial resistance in major pathogens in a local setting are very important to select appropriate antibiotics for the treatment of CAP. Major identifiable pathogens of CAP include *Streptococcus pneumoniae*, *Haemophilus influenzae* and atypical pathogens such as *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and *Legionella* spp. [@bib1], [@bib2], [@bib3]. However, the distribution of aetiological pathogens of CAP may vary by country. Most of the data on pathogen distribution of CAP have been reported from western countries, whilst only a few data are available in the Asian region [@bib2], [@bib3], [@bib4], [@bib5], [@bib6]. The recent emergence of antimicrobial resistance in major respiratory pathogens, especially in *S. pneumoniae*, is another critical point for appropriate treatment of CAP. Previous data by the Asian Network for Surveillance of Resistant Pathogens (ANSORP) showed that Asian countries have very serious problems of increasing prevalence and level of antimicrobial resistance to penicillin and macrolides in pneumococcal isolates [@bib7], [@bib8].

Although several treatment guidelines have been proposed by different organisations, such as the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS)(2007), the Canadian Society of Infectious Diseases (2000) and Drug-Resistant *Streptococcus pneumoniae* (DRSP) Therapeutic Working Group (2000), treatment recommendations for CAP in Asian countries should be based on the epidemiological information of pathogen distribution and antimicrobial resistance among major respiratory pathogens in the Asian region.

This multinational surveillance study by ANSORP was performed to investigate the epidemiology of aetiological pathogens of CAP in Asian countries, including usual bacterial pathogens and atypical pathogens, as well as to evaluate the clinical outcomes and risk factors of CAP in Asian countries.

2. Materials and methods {#section0010}
========================

2.1. Participating centres {#section0015}
--------------------------

ANSORP conducted a prospective surveillance study from January 2002 to December 2004 in 14 tertiary care hospitals in eight Asian countries: South Korea (Samsung Medical Center, Gangbuk Samsung Hospital, Seoul Veterans Hospital, Seoul; Kyungpook National University, Daegu; Chungnam National University, Daejeon; and Chonnam National University, Gwangju); China (Chao Yang Hospital, Beijing; and Rui Jin Hospital, Shanghai); Taiwan (Chang Gung Memorial Hospital and National Taiwan University, Taipei); Hong Kong (Princess Margaret Hospital, Hong Kong); India (Christian Medical College, Vellore); Singapore (Singapore General Hospital, Singapore); Vietnam (University of Medicine and Pharmacy, HCMC, Vietnam); and The Philippines (Research Institute of Tropical Medicine, Manila).

2.2. Study population and design {#section0020}
--------------------------------

Any adult patient who fulfilled all of the following criteria with clinical and radiological diagnosis of CAP was eligible for the study. CAP was defined as follows: (1) new or progressive infiltrate(s), consolidation or pleural effusion consistent with pneumonia on chest radiography performed within 48 h prior to enrolment; (2) fever or a history of fever (defined as an oral temperature \> 38 °C); and (3) at least two respiratory signs and symptoms (new or increased cough; purulent sputum or a change in sputum characteristics; auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation; dyspnoea or tachypnoea; peripheral white blood cell (WBC) count \>10 000 cells/mm^3^ or \>15% immature neutrophils or leukopenia with a total WBC count of \<4500 cells/mm^3^; hypoxemia with a partial pressure of oxygen in arterial blood (PaO~2~) \<60 mmHg while the patient is breathing room air). Patients younger than 15 years of age, patients who had been hospitalised for more than 72 h or who had been discharged from an acute care hospital within 10 days, patients who had organ transplantation within 6 months, patients with severe acute respiratory syndrome (SARS) or known human immunodeficiency virus (HIV)-infected patients were excluded from the study.

All enrolled patients were evaluated with regard to clinical, radiological and microbiological findings. All available clinical, laboratory and radiological information was recorded. The presence of the following co-morbid conditions was determined by patient report or chart review: bronchopulmonary disease (i.e. asthma, chronic obstructive pulmonary disease or interstitial lung disease); congestive heart failure; coronary artery disease; malignancy; cerebrovascular disease; renal disease; and immunosuppression. Based on these findings, risk class was determined according to the criteria from the Pneumonia Patient Outcomes Research Team (PPORT) study [@bib9].

For this study, no specific antibiotic regimens were recommended. Use of antimicrobial agents in each centre was recorded, and follow-up evaluation was done for clinical, radiological and microbiological responses to antimicrobial therapy. The clinical outcome was measured by the 30-day mortality rate.

2.3. Microbiological evaluation {#section0025}
-------------------------------

At the time of enrolment, sputum cultures, blood cultures (if feasible) and serological tests for atypical pathogens were performed. All microbiological evaluations were performed before initiation of antimicrobial treatment. All sputum specimens and other samples of respiratory secretions were Gram stained and examined microscopically for the presence of WBCs, epithelial cells and bacteria. Purulence was measured by microscopy and was acceptable if there was \>25 WBCs and \<10 squamous epithelial cells. Results from sputum cultures were only considered significant if the above Gram-stain criteria were satisfied.

Given their practical performance, cost, specificity and sensitivity, three serological kits were chosen for detection of atypical pathogens. To detect *M. pneumoniae* and *C. pneumoniae* in all enrolled patients, PLATELIA^®^ *M. pneumoniae* kit (Bio-Rad, Marnes-la-Coquette, France) and *C. pneumoniae* EIA kit (Thermo Labsystems, Helsinki, Finland) were used according to the manufacturers' instructions, which consist of 96-well microplates using enzyme-linked immunosorbent assay (ELISA). These were kits for detecting immunoglobulin G (IgG) and IgM class antibodies. The presence of IgM antibodies allowed the diagnosis of acute infection directly on the first serum sample. If the result of IgM was negative or equivocal, IgG was tested on the first serum (stored after IgM test) and on the second serum (second blood sampling after 8--15 days) samples. If the second titre of IgG increased more than twice compared with the first titre, acute infection was confirmed. To detect *Legionella pneumophila* in all enrolled patients, NOW^®^ Legionella urinary antigen test (Binax Inc., Scarborough, ME) was used, which is an in vitro rapid immunochromatographic assay for the qualitative detection of *L. pneumophila* serogroup 1 antigen in urine specimens from patients with symptoms of pneumonia.

The aetiology of pneumonia was confirmed if one of the following criteria was met: (1) blood cultures yielding a bacterial or fungal pathogen (in the absence of an apparent extrapulmonary focus); (2) pleural fluid or transthoracic needle aspiration cultures yielding a bacterial pathogen; (3) seroconversion (i.e. a four-fold increase in IgG titres); (4) a single increased IgM titre for *C. pneumoniae* or *M. pneumoniae*; (5) positive urinary antigen for *L. pneumophila* or *S. pneumoniae*; and (6) bacterial growth in cultures of bronchoalveolar lavage (BAL) fluid ≥10^4^ colony-forming units/mL. The aetiology was considered presumptive if a valid sputum sample yielded one or more predominant bacterial strains [@bib4], [@bib5].

2.4. Antimicrobial susceptibility tests {#section0030}
---------------------------------------

Bacterial isolates from initial cultures were subjected to in vitro testing in each local microbiology laboratory as usual. All isolates were sent to the Central Laboratory (Samsung Medical Center, Seoul, South Korea) for further in vitro testing with various antimicrobial agents. Antimicrobial susceptibility tests were performed by the broth microdilution method according to the standards of the Clinical and Laboratory Standards Institute. Antimicrobial agents tested were penicillin, amoxicillin/clavulanic acid, cefuroxime, ceftriaxone, imipenem, erythromycin, azithromycin, ciprofloxacin, levofloxacin, teicoplanin and vancomycin.

2.5. Statistical analysis {#section0035}
-------------------------

Student\'s *t*-test was used to compare continuous variables and *χ* ^2^ or Fisher\'s exact test to compare categorical variables. In identifying the independent risk factors for mortality, a stepwise conditional logistic regression analysis was used to control for the effects of confounding variables. All *P*-values were two-tailed and *P*-values \<0.05 were considered statistically significant.

3. Results {#section0040}
==========

3.1. Patient characteristics {#section0045}
----------------------------

A total of 1031 cases were enrolled in the study from 14 centres from January 2002 to December 2004, but 76 cases were excluded owing to inadequate medical records. Therefore, a total of 955 cases (604 men and 351 women) fulfilling diagnostic criteria of CAP were evaluated; 338 (35.4%) from Korea, 114 (11.9%) from Hong Kong, 111 (11.6%) from China, 104 (10.9%) from India, 96 (10.1%) from Singapore, 72 (7.5%) from Vietnam, 65 (6.8%) from Taiwan and 55 (5.8%) from The Philippines.

Demographic characteristics of the patients are shown in [Table 1](#tbl1){ref-type="table"} . The mean age (± standard deviation) of the patients was 57.3 ± 13.7 years (range 16--94 years). Bronchopulmonary disease (29.9%) was the most frequent underlying disease, followed by cardiovascular diseases (19.9%), malignancy (11.7%) and neurological disorders (8.2%) ([Table 1](#tbl1){ref-type="table"}). A smoking history was reported in 238 patients (26.1%), and 230 patients (30.3%) had a history of prior antibiotic use.Table 1Demographic and clinical characteristics of the study populationCharacteristicNo. of patients (%) (*n* = 955)[a](#tbl1fn1){ref-type="table-fn"}Age, mean ± S.D. (range) (years)57.3 ± 13.7 (16--94)Male604 (63.2)  Underlying diseases Bronchopulmonary disorder286 (29.9) Cardiovascular disorder190 (19.9) Neoplastic disorder112 (11.7) Neurological disorder78 (8.2) Liver disorder42 (4.4) Renal disorder39 (4.1) Asplenia or hyposplenia7 (0.7) None278 (29.1)  Co-morbid conditions Neutropenia33/912 (3.6) Use of immunosuppressant25/912 (2.7) Use of corticosteroid18/912 (2.0) Smoking238/912 (26.1) High alcohol intake60/912 (6.6) Residence in nursing home29/912 (3.2) Recent hospitalisation69/912 (7.6) Prior use of antimicrobial agent230/760 (30.3)[^1][^2]

3.2. Clinical manifestations {#section0050}
----------------------------

The clinical, laboratory and radiological findings of patients at enrolment are summarised in [Table 2](#tbl2){ref-type="table"} . Cough (92.8%) was the most common symptom, and 10.7% of patients (86/801) presented with altered mentality. Leukocytosis (WBC \> 10 000/mm^3^), azotaemia (blood urea nitrogen \> 30 mg/dL) and hypoxaemia (PaO~2~  \< 60 mmHg or arterial oxygen saturation (SaO~2~) \< 90%) were also observed in 66.7%, 19.4% and 14.7%, respectively ([Table 2](#tbl2){ref-type="table"}). Multiple lobes were involved in 35.3% of patients and pleural effusion was found in 15.0%.Table 2Clinical manifestations and laboratory findings at initial presentationFindingsNo. of patients (%) (*n* = 955)[a](#tbl2fn1){ref-type="table-fn"}Symptoms Cough743/801 (92.8) Purulent sputum684/776 (88.1) Dyspnoea479/766 (62.5) Chest pain264/941 (28.1) Altered mentality86/801 (10.7)  Signs Respiratory rate \>30/min89/955 (9.3) Heart rate ≥125/min66/955 (6.9) Temperature ≥40 °C or \< 35 °C52/955 (5.4) SBP \<90 mmHg29/955 (3.0)  Laboratory findings WBC ≥10 000/mm^3^588/882 (66.7) BUN ≥ 30 mg/dL164/847 (19.4) PaO~2~ \<60 mmHg or SaO~2~ \< 90%122/831 (14.7) Haematocrit \<30%97/879 (11.0) Serum sodium \<130 mEq/L79/856 (9.2) Glucose ≥250 mg/dL75/840 (8.9) Arterial pH \<7.3552/750 (6.9)  Radiological findings Lobar pneumonia380/861 (44.1) Bronchopneumonia396/861 (46.0) Interstitial pneumonia85/861 (9.9) Multilobar involvement303/859 (35.3) Pleural effusion137/915 (15.0)  Pneumonia severity index I214/929 (23.0) II281/929 (30.2) III170/929 (18.3) IV193/929 (20.8) V71/929 (7.6)[^3][^4]

The disease severity of pneumonia in 929 patients was classified based on PORT criteria at the time of enrolment. Patients belonged to the following classes: 214 (23.0%) to class I; 281 (30.2%) to class II; 170 (18.3%) to class III; 193 (20.8%) to class IV; and 71 (7.6%) to class V. Overall, 593 patients (62.1%) were admitted to hospital and 56 patients (5.9%) were admitted to the Intensive Care Unit.

3.3. Aetiology of CAP {#section0055}
---------------------

A microbiological aetiology could be determined in 428 (44.8%) of the 955 patients, which was definitive in 223 (52.1%) of cases and presumptive in 205 (47.9%).

Overall, a total of 390 bacterial pathogens were isolated from 349 patients (36.5%). The most common specimen source was sputum (76.4%), followed by blood (6.4%), pleural fluid (4.4%), BAL (2.8%) and other specimens (10.0%). Of the 390 isolates, *S. pneumoniae* (29.2%) was the most frequent isolate, followed by *Klebsiella pneumoniae* (15.4%), *H. influenzae* (15.1%), *Pseudomonas aeruginosa* (6.7%), *Staphylococcus aureus* (4.9%), *Mycobacterium tuberculosis* (3.3%) and *Moraxella catarrhalis* (3.1%) ([Table 3](#tbl3){ref-type="table"} ).Table 3Aetiological distribution of community-acquired pneumonia in Asian countriesAetiologyNo. of isolates (%)Pathogens isolated *(n* = 390) *Streptococcus pneumoniae*114 (29.2) *Klebsiella pneumoniae*60 (15.4) *Haemophilus influenzae*59 (15.1) *Pseudomonas aeruginosa*26 (6.7) *Staphylococcus aureus*19 (4.9) *Mycobacterium tuberculosis*13 (3.3) *Moraxella catarrhalis*12 (3.1) Other pathogens77 (19.7) *Mycoplasma pneumoniae*61/556 (11.0) *Chlamydia pneumoniae*55/411 (13.4) *Legionella pneumophila*7/648 (1.1)  Mixed infections (*n* = 60) *S. pneumoniae* + *C. pneumoniae*9 (15.0) *S. pneumoniae* + *M. pneumoniae*5 (8.3) *S. pneumoniae* + *K. pneumoniae*5 (8.3) *S. pneumoniae* + *M. catarrhalis*4 (6.7) *S. pneumoniae* + other pathogen3 (5.0) *H. influenzae* + *K. pneumoniae*5 (8.3) *H. influenzae* + *M. catarrhalis*3 (5.0) *H. influenzae* + *C. pneumoniae*2 (3.3) *H. influenzae* + other pathogen2 (3.3) *K. pneumoniae* + *C. pneumoniae*2 (3.3) *K. pneumoniae* + other pathogen2 (3.3) *C. pneumoniae* + *M. tuberculosis*1 (1.7) *M. pneumoniae* + *P. aeruginosa*1 (1.7) *S. pneumoniae* + *H. influenzae* + *C. pneumoniae*1 (1.7) *S. pneumoniae* + *C. pneumoniae* + virus1 (1.7) *S. pneumoniae* + other pathogens1 (1.7) *H. influenzae* + *K. pneumoniae* + *P. aeruginosa*1 (1.7) Other pathogens12 (20.0)

For serological tests of *M. pneumoniae* and *C. pneumoniae*, paired sera were obtained from 556 and 411 patients, respectively. Of these, positive serological results were obtained from 61 (11.0%) for *M. pneumoniae* and 55 (13.4%) patients for *C. pneumoniae*. For urinary antigen tests of *L. pneumophila*, urine samples were obtained from 648 patients and only 7 (1.1%) of them were positive for *L. pneumophila*.

Of 349 patients with bacterial pathogens isolated, mixed infections were found in 60 patients (17.2%) as follows: 44 patients with two different pathogens, 8 patients with three different pathogens and 8 patients with four different pathogens ([Table 3](#tbl3){ref-type="table"}). The most frequent combination was *S. pneumoniae* with *C. pneumoniae* (9/60; 15.0%). Mixed infections were found in 25.4% (29/114) of patients with pneumococcal pneumonia.

3.4. Antimicrobial susceptibility testing {#section0060}
-----------------------------------------

The results of antimicrobial susceptibility testing against major pathogens are summarised in [Table 4](#tbl4){ref-type="table"} . Of 57 pneumococcal isolates available, 30 (52.6%) isolates were not susceptible to penicillin: 10 (17.5%) were penicillin intermediate (minimum inhibitory concentration (MIC) = 0.12--1 μg/mL) and 20 (35.1%) were penicillin resistant (MIC ≥ 2 μg/mL). Resistance rates to erythromycin, cefuroxime and ceftriaxone were 56.1%, 47.4% and 7.0%, respectively. No pneumococcal isolates were resistant to vancomycin or levofloxacin.Table 4Antimicrobial susceptibility of major pathogensMajor pathogensNo. of isolates (%)MIC~90~ (μg/mL)SIR*Streptococcus pneumoniae* (*n* = 57) Penicillin[a](#tbl4fn1){ref-type="table-fn"}27 (47.4)10 (17.5)20 (35.1)2 Amoxicillin/clavulanic acid49 (86.0)6 (10.5)2 (3.5)4/2 Erythromycin25 (43.9)032 (56.1)\>32 Cefuroxime[b](#tbl4fn2){ref-type="table-fn"}30 (52.6)027 (47.4)8 Ceftriaxone[b](#tbl4fn2){ref-type="table-fn"}38 (66.7)15 (26.3)4 (7.0)1 Levofloxacin57 (100.0)001 Vancomycin57 (100.0)000.25  *Haemophilus influenzae* (*n* = 16) Amoxicillin/clavulanic acid16 (100.0)000.5/0.25 Cefuroxime15 (93.8)01 (6.3)1 Ceftriaxone15 (93.8)01 (6.3)1 Azithromycin14 (87.5)02 (12.5)2 Ciprofloxacin16 (100.0)001 Imipenem16 (100.0)002  *Klebsiella pneumoniae* (*n* = 36) Amoxicillin/clavulanic acid27 (75.0)1 (2.8)8 (22.2)64/32 Cefuroxime32 (88.9)04 (11.1)64 Ceftriaxone35 (97.2)01 (2.8)0.5 Ciprofloxacin36 (100.0)000.25 Imipenem36 (100.0)000.5[^5][^6][^7]

Of 16 *H. influenzae* isolates, 2 isolates (12.5%) were resistant to azithromycin and all isolates were susceptible to amoxicillin/clavulanic acid, ciprofloxacin and imipenem.

Of 36 *K. pneumoniae* isolates, resistance rates to cefuroxime and ceftriaxone were 11.1% and 2.8%, respectively. All *K. pneumoniae* isolates were susceptible to ciprofloxacin and imipenem ([Table 4](#tbl4){ref-type="table"}).

3.5. Antimicrobial therapy {#section0065}
--------------------------

In all 955 cases, antimicrobial therapy was initiated within 24 h after enrolment. Five hundred and forty-two patients (56.8%) received combination therapy as an initial empirical antimicrobial therapy. Of these, third-generation cephalosporin + macrolide (41.3%) was the most frequently prescribed combination regimen, followed by penicillin + macrolide (16.2%), third-generation cephalosporin + fluoroquinolone (7.7%) and penicillin + aminoglycoside (6.3%). Four hundred and thirteen patients (43.2%) received monotherapy as the empirical antimicrobial therapy. Of these, penicillin (36.8%) was the most common agent followed by fluoroquinolone (25.7%), third-generation cephalosporin (17.4%), second-generation cephalosporin (4.6%) and macrolide (3.4%).

3.6. Clinical outcomes of CAP {#section0070}
-----------------------------

The clinical outcomes were evaluated in 885 cases that had submitted relevant data for outcome analysis. The overall 30-day mortality rate was 7.3% (65/885). Of 882 patients who were evaluated by the PORT classification, mortality rates were 0.5% in class I (1/201), 1.6% in class II (4/253), 5.4% in class III (9/167), 12.6% in class IV (24/190) and 38.0% in class V (27/71).

With regard to the final clinical outcomes, clinical improvement without modification of antibiotics (58.6%), clinical improvement with modification of antibiotics (18.9%) and death due to pneumonia aggravation (5.9%) were observed, whilst clinical outcomes were undetermined in 16.6% of cases.

In the univariate analyses, risk factors for mortality included old age, nursing home residence, malignancy, cardiovascular diseases, renal diseases, prior hospitalisation, altered mentality, respiratory rate \>30/min, systolic blood pressure \<90 mmHg, pulse rate \>125/min, leukocytosis, azotaemia, hypoxaemia, hyponatraemia, high glucose level, low haematocrit, multilobar involvement, pleural effusion and mechanical ventilation (all *P*  \< 0.05) ([Table 5](#tbl5){ref-type="table"} ). Multivariate analysis using a logistic regression model, including the variables associated with mortality by univariate analysis (*P*  \< 0.05), showed that nursing home residence, mechanical ventilation, malignancy, cardiovascular diseases, respiratory rate \> 30/min and hyponatraemia were independent risk factors for mortality (*P*  \< 0.05) ([Table 6](#tbl6){ref-type="table"} ).Table 5Factors associated with 30-day mortality in patients with community-acquired pneumonia in the univariate analysisSurvivors (*n* = 820)[a](#tbl5fn1){ref-type="table-fn"}Non-survivors (*n* = 65)[a](#tbl5fn1){ref-type="table-fn"}OR (95% CI)*P*-valueOld age (≥65 years)160/820 (19.5)20/65 (30.8)1.83 (1.05--3.19)0.037Residence in nursing home23/820 (2.8)6/65 (9.2)3.52 (1.38--8.99)0.015  Underlying diseases Bronchopulmonary disorder258/820 (31.5)20/65 (30.8)0.97 (0.56--1.67)0.908 Cardiovascular disorder165/820 (20.1)25/65 (38.5)2.48 (1.46--4.21)0.001 Malignancy92/820 (11.2)16/65 (24.6)2.58 (1.41--4.73)0.001 Neurological disorder69/820 (8.4)9/65 (13.8)1.75 (0.83--3.69)0.137 Liver disorder37/820 (4.5)5/65 (7.7)1.76 (0.67--4.65)0.22 Renal disorder32/820 (3.9)6/65 (9.2)2.50 (1.01--6.23)0.053  Co-morbid condition Neutropenia28/820 (3.4)4/65 (6.2)1.86 (0.63--5.46)0.286 Corticosteroid use17/820 (2.1)1/65 (1.5)0.74 (0.10--5.64)1.000 Immunosuppressant use23/820 (2.8)2/65 (3.1)1.10 (0.25--4.77)0.705 Smoking215/820 (26.2)21/65 (32.3)1.34 (0.78--2.31)0.285 Alcoholism53/820 (6.5)6/65 (9.2)1.47 (0.61--3.57)0.433 Recent hospitalisation54/820 (6.6)13/65 (20.0)3.55 (1.82--6.91)0.001 ICU admission35/819 (4.3)33/65 (50.8)23.10 (12.77--41.78)\<0.001 Mechanical ventilation24/729 (3.3)36/57 (63.2)50.36 (25.65--98.87)\<0.001  Symptoms and signs Dyspnoea419/698 (60.0)56/63 (88.9)5.33 (2.39--11.86)\<0.001 Chest pain243/687 (35.4)21/57 (36.8)1.07 (0.61--1.87)0.824 Altered mentality63/731 (8.6)23/65 (35.4)5.81 (3.28--10.27)\<0.001 Temperature ≥40 °C or \< 35 °C39/820 (4.8)4/65 (6.2)1.31 (0.45--3.80)0.549 Respiratory rate \> 30/min63/820 (7.7)25/65 (38.5)7.51 (4.28--13.17)\<0.001 SBP \< 90 mmHg22/820 (2.7)7/65 (10.8)4.38 (1.79--10.67)0.004 Pulse rate \> 125/min56/820 (6.8)9/65 (13.8)2.19 (1.03--4.66)0.047  Laboratory findings WBC ≥ 10 000/mm^3^531/814 (65.2)54/63 (85.7)3.19 (1.56--6.57)0.001 BUN ≥ 30 mg/dL139/783 (17.8)24/59 (40.7)3.18 (1.83--5.51)\<0.001 PaO~2~ \< 60 mmHg or SaO~2~ \< 90%93/764 (12.2)29/63 (46.0)6.15 (3.58--10.57)\<0.001 Haematocrit \< 30%81/812 (10.0)14/62 (22.6)2.63 (1.39--4.98)0.002 Serum sodium \< 130 mEq/L62/789 (7.9)16/62 (25.8)4.08 (2.18--7.62)\<0.001 Glucose ≥ 250 mg/dL63/775 (8.1)12/61 (19.7)2.77 (1.40--5.47)0.002 Arterial pH \< 7.3534/690 (4.9)18/59 (30.5)8.47 (4.41--16.27)\<0.001  Pneumonia severity index I200/817 (24.5)1/65 (1.5)--\<0.001 II249/817 (30.5)4/65 (6.2)-- III158/817 (19.3)9/65 (13.8)-- IV166/817 (20.3)24/65 (36.9)-- V44/817 (5.4)27/65 (41.5)-- Multilobar involvement256/755 (33.9)32/56 (57.1)2.60 (1.49--4.51)\<0.001 Pleural effusion116/805 (14.4)15/62 (24.2)1.89 (1.03--3.50)0.038 *Streptococcus pneumoniae*100/820 (12.2)11/65 (16.9)1.47 (0.74--2.89)0.268 Atypical pneumonia89/820 (10.9)4/65 (6.2)0.54 (0.19--1.52)0.234 Combination therapy455/798 (57.0)41/65 (63.1)1.29 (0.76--2.17)0.342[^8][^9]Table 6Multivariate analysis of independent risk factors for mortality in 777 patients with community-acquired pneumoniaVariableAdjusted OR (95% CI)*P*-valueMechanical ventilation43.75 (20.16--94.97)\<0.001Nursing home residence6.78 (2.11--21.85)0.001Respiratory rate \> 30/min5.91 (2.53--13.85)\<0.001Hyponatraemia4.08 (1.66--10.03)0.002Malignancy2.88 (1.67--7.14)0.022Cardiovascular diseases2.83 (1.33--6.00)0.007[^10]

4. Discussion {#section0075}
=============

The current data provided a comprehensive evaluation of causes and outcomes of patients with CAP in Asian countries from a large, prospective, multicentre study. This ANSORP study highlights several characteristics of CAP in Asian countries: the high prevalence of *S. pneumoniae* as an aetiological pathogen; the relatively high prevalence of mixed infections by bacteria and atypical pathogens; antimicrobial practice for the treatment of CAP; clinical outcomes; and risk factors for mortality. Demographic characteristics of the patients in this study were similar with those in previous data from other regions [@bib2], [@bib3], [@bib4], [@bib5], [@bib6]. Approximately 71% of all enrolled patients had at least one co-morbid condition, including bronchopulmonary disorder, cardiovascular disorder, malignancy and neurological disorder. There were no significant differences in the clinical presentations between CAP caused by typical bacterial pathogens and atypical pathogens (data not shown).

In this study, aetiological pathogens were identified in 44.8% of cases based on microbiological or serological studies. The relatively low percentage of cases with identifiable aetiology might be due to prior antibiotic use before cultures and difficulties in obtaining adequate sputum specimen [@bib3], [@bib4]. Approximately 30% of cases had received antimicrobial therapy before enrolment in this study. Among identified aetiologies, *S. pneumoniae* was the most common pathogen, as previously reported from other regions [@bib4], [@bib5]. In vitro resistance to penicillin, macrolides and other antimicrobial agents in pneumococcal isolates from this study was consistent with findings from previous ANSORP studies in Asian countries [@bib7], [@bib8]. In particular, a high prevalence of erythromycin resistance with a very high MIC level would preclude the use of macrolides as first-line agents for the treatment of CAP in many Asian countries.

Prevalence rates of *M. pneumoniae* and *C. pneumoniae* in Asian countries were comparable with those in other regions [@bib4], [@bib5], [@bib6]. Approximately 25% of CAP cases in Asian countries were caused by these atypical pathogens. Interestingly, however, the incidence of CAP caused by *Legionella* spp. was extremely low (1.1%) in this study. Although the incidence of *Legionella* pneumonia was low in this study, it has been reported as one of the most common atypical pathogens of CAP around the world [@bib3], [@bib5]. Another important finding from this study was the relatively high incidence of mixed infections by typical bacteria and atypical pathogens. The significance and frequency of mixed infections in CAP, mainly mixed bacterial--viral infections, has been increasingly reported [@bib5]. Although we did not evaluate the viral aetiology in this study, 17% of CAP cases were caused by multiple pathogens such as *S. pneumoniae* and *C. pneumoniae* or *S. pneumoniae* and *M. pneumoniae*. This epidemiological finding is important in clinical practice because this type of mixed infection may result in treatment failure of monotherapy with β-lactam agents. Tuberculosis (TB) was diagnosed in 13 patients, which showed the same clinical presentations as bacterial pneumoniae. TB should be considered the possible cause of CAP, especially in areas where TB is endemic [@bib4], [@bib10].

Selection of appropriate antimicrobial agents is essential for the treatment of CAP, which should be based on suspected microorganisms, risk factors and severity of illness [@bib1]. According to the recent IDSA/ATS guidelines, macrolides, doxycycline or fluoroquinolones are recommended as a monotherapy option for treating outpatients with CAP [@bib1]. However, macrolides or doxycycline may not be appropriate options for treatment of outpatients with CAP in Asian countries where resistance to macrolides and tetracycline is very prevalent [@bib7]. Also, single use of β-lactam agents would result in clinical failure if CAP is caused by multiple agents including atypical pathogens. The current study showed that regardless of microorganisms, risk factors and severity of CAP, a combination regimen, especially third-generation cephalosporin + macrolide, is one of the most common regimens used for treatment of patients with CAP in Asian countries.

The overall mortality rate of CAP was 7.3%, and one-half of cases died of uncontrolled pneumonia. The current study could identify the risk factors for death, which would be similar to those documented in other studies [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16]. Among independent risk factors identified in this study, hyponatraemia is a common complication present at the time of admission for CAP that is associated with more severe illness [@bib17].

Our study may have some limitations. First, the number of cases with CAP from each country is relatively small, which may not represent the national status of pathogen distribution and antimicrobial resistance in these pathogens. Second, since we did not evaluate viral aetiology, we could not estimate the true incidence of mixed infections.

In conclusion, data from this study could provide a better understanding of the aetiology, risk factors, clinical characteristics and outcomes of CAP in Asian countries. Given the prevalence of major bacterial pathogens and antimicrobial susceptibility as well as incidence of atypical pathogens and mixed infections, appropriate antimicrobial options could be recommended for Asian countries.
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[^1]: S.D., standard deviation.

[^2]: Exact numbers are given for each variable; information was not available for all patients. Unless otherwise indicated, data represent number of patients (%).

[^3]: SBP, systolic blood pressure; WBC, white blood cells; BUN, blood urea nitrogen; PaO~2~, partial pressure of oxygen in arterial blood; SaO~2~, arterial oxygen saturation.

[^4]: Exact numbers are given for each variable; information was not available for all patients.

[^5]: S, susceptible; I, intermediate; R, resistant; MIC, minimum inhibitory concentration; MIC~90~, MIC of 90% of the organisms.

[^6]: Susceptible, MIC ≤ 0.1 μg/mL; intermediate, MIC = 0.12--1 μg/mL; resistant, MIC ≥ 2 μg/mL.

[^7]: Susceptible, MIC ≤ 1 μg/mL; intermediate, MIC = 2 μg/mL; resistant, MIC ≥ 4 μg/mL.

[^8]: OR, odds ratio; CI, confidence interval; ICU, Intensive Care Unit; SBP, systolic blood pressure; WBC, white blood cells; BUN, blood urea nitrogen; PaO~2~, partial pressure of oxygen in arterial blood; SaO~2~, arterial oxygen saturation.

[^9]: Exact numbers are given for each variable; information was not available for all patients.

[^10]: OR, odds ratio; CI, confidence interval.
